American Journal of Psychiatry
July 1, 2004
Ralph Buchert, Rainer Thomasius, Florian Wilke et al.
183 citations
These findings support the hypothesis of MDMA-induced protracted alterations of the serotonergic system and indicate that the reduced availability of serotonin transporter, as measured by PET, might be reversible. Women appear to be more susceptible than men to MDMA-induced alterations of the serotonergic system.
European Journal of Neuroscience
July 1, 2004
Paul Brown, Eugene A. Kiyatkin
105 citations
Abstract Drugs of abuse, such as 3,4‐methylenedioxymethamphetamine (MDMA), often have more powerful effects during states of increased activation and under specific environmental conditions. Because hyperthermia is a major complication of MDMA use and a factor potentiating neurotoxicity, we examined the effects of this drug (9 mg/kg, sc; approximately one‐fifth of the known LD 50 in rats) on...
International Journal of Developmental Neuroscience
June 5, 2004
Jerrold S. Meyer, Mark Grande, Kenneth M Johnson et al.
50 citations
Abstract 3,4‐Methylenedioxymethamphetamine damages fine serotonergic fibers and nerve terminals in adult organisms. Developing animals seem to be less susceptible to this effect, possibly due to a lack of drug‐induced hyperthermia. We tested this hypothesis by producing hyperthermia in neonatal rats for 2 h after each of twice‐daily MDMA (10 mg/kg s.c.) or saline injections administered from...
A Handbook on Drug and Alcohol Abuse
June 3, 2004
Gail Winger, James H Woods, Frederick G Hofmann
Abstract Club drugs are typically taken by groups of people during raves. Raves are parties where the opportunity to dance to very loud, rhythmic music while under the influence of one or more drugs is the primary attraction. Needless to say, most users of club drugs under these conditions are young and single. Club drugs are usually taken periodically; several of them may be taken three to...
Addictive Behaviors
June 2004
Andrew Scholey, Andrew C. Parrott, Tom Buchanan et al.
Recreational Ecstasy/MDMA (3,4-methylenedioxymethamphetamine) users often take a variety of psychoactive drugs, but there is little empirical data on how these drug consumption patterns change with greater experience of Ecstasy. The aim of this study was to compare the polydrug usage patterns reported by non-Ecstasy users, novice Ecstasy users, moderate Ecstasy users, and heavy Ecstasy users....
British Journal of Pharmacology
June 1, 2004
Jon E. Sprague, Robert E. Brutcher, Edward Mills et al.
53 citations
Studies were designed to examine the effects of α 1 ( α 1 AR)‐ plus β 3 ‐adrenoreceptor ( β 3 AR) antagonists on 3,4‐methylenedioxymethamphetamine (MDMA, Ecstasy)‐induced hyperthermia and measures of rhabdomyolysis (creatine kinase (CK)) and renal function (blood urea nitrogen (BUN) and serum creatinine (sCr)) in male Sprague–Dawley rats. MDMA (40 mg kg −1 , s.c.) induced a rapid and robust...
Journal of Psychoactive Drugs
June 1, 2004
Robert G. Carlson, Rüssel S. Falck, Jill A. McCaughan et al.
49 citations
In the past several years, the use of MDMA (Ecstasy) has increased substantially in the United States and in many countries around the world. Although this increase has been associated with the dance club and rave scenes, Ecstasy use has expanded into new settings. At the same time, the diversity of people using the drug has also grown. Given the increasing, although unclear, evidence that MDMA...
CNS Drug Reviews
June 1, 2004
Roland W. Freudenmann, Manfred Spitzer
41 citations
ABSTRACT This paper reviews the pharmacology and toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA, “eve”). MDEA is a ring‐substituted amphetamine (RSA) like MDMA, its well known N‐methyl analog. Both have become very popular substances of abuse in the techno‐ and house‐music scene. They can evoke psychomotor stimulation, mild alterations of perception, sensations of closeness and a...
Drugs Education Prevention and Policy
June 1, 2004
Sarah Riley, Emma Hayward
52 citations
A survey of drug use in the past year was completed by 124 clubbers (50% male, 50% female, age range 14–44, mean 24 years). Participants were self selecting and recruited in clubs and pre-club bars. Prevalence rates for alcohol, cannabis, and ecstasy were over 80%; 63% reported cocaine and 53% amphetamine use, 15%–43% used ketamine, psilocybin, LSD and nitrites. A pattern of polydrug and...
Neuroscience Letters
May 13, 2004
Marie-Louise Sveen, Gitte M. Knudsen, Susana Aznar
MDMA (3,4 Methylenedioxy-methamphetamine) binds and blocks the presynaptic serotonin reuptake transporters and postsynaptic serotonin 5-HT2A receptors, with highest affinity for the first. Whether 5-HT2A receptor density decreases due to MDMA's direct effect on postsynaptic serotonin receptors is at present not known. This study analyzes whether direct stimulation of the postsynaptic 5-HT2A...
Human Psychopharmacology: Clinical and Experimental
May 5, 2004
Michelle Wareing, John E. Fisk, Philip N. Murphy et al.
76 citations
Abstract Previous research suggests that MDMA users are impaired in various aspects of cognitive functioning, however, it remains unclear whether they might experience deficits in established measures of verbal working memory functioning. In the present study current and previous MDMA users were compared with non‐users on verbal working memory measures including reading and computation span....
Psychopharmacology
May 2004
Karsten Heekeren, Jörg Daumann, Mark A. Geyer et al.
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is neurotoxic upon central serotonin systems in experimental animals and probably also in humans. Serotonin is involved in the habituation, sensitization and prepulse inhibition (PPI) of the startle reflex. To study the plasticity of startle reflex in currently abstinent MDMA users. Electromyographic responses to acoustic startle stimuli (pulse...
Psychopharmacology
May 2004
Thomas J R Beveridge, Annis O. Mechan, Marie Sprakes et al.
3,4-Methylenedioxymethamphetamine (MDMA) administration to rats produces an acute hyperthermic response and induces localised neuronal activation, which can be visualised via expression of immediate-early genes. The pharmacological and anatomical basis of these effects are unclear. At high doses, MDMA also causes selective neurotoxicity at serotonergic nerve terminals. We investigated the...
Psychopharmacology
May 2004
M Farré, Rafael de la Torre, Brian O Mathúna et al.
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") is increasingly used by young people for its euphoric and empathic effects. MDMA presents non-linear pharmacokinetics, probably by inhibition of cytochrome P450 isoform 2D6. Users are known to often take more than one dose per session. This practice could have serious implications for the toxicity of MDMA. To evaluate the pharmacological...
Nature
May 1, 2004
Psychedelic drugs: the ups and downs of ecstasy.
Psychopharmacology
May 2004
Fabrizio Schifano
The issue of ecstasy-related fatalities has extensively attracted the attention of both the media and the general public, but less so of the scientific literature. The aim of the present review is to focus on the epidemiological, clinical and pharmacological issues related to ecstasy fatalities. Possibly due to a number of different reasons, the rates of ecstasy-related deaths seem to have...
Psychopharmacology
May 2004
Jonathan P. Roiser, Barbara J. Sahakian
3,4-Methylenedioxymethamphetamine (MDMA or "ecstasy") causes serotonin neuron damage in laboratory animals. The serotonin system is known to be important in the regulation of mood. Previous research has shown that MDMA users score higher on self-report ratings of depression than controls. However, MDMA users commonly take other illicit substances and many studies do not fully control for...
Neuropsychopharmacology
May 2004
Boris B. Quednow, Kai‐uwe Kühn, Klaus Hoenig et al.
Chronic administration of 3,4-methylenedioxymethamphetamine (MDMA) is associated with long-term depletion of serotonin (5-HT) and loss of 5-HT axons in the brains of rodents and nonhuman primates. Despite the broad database concerning the selective serotonergic neurotoxicity of recreational MDMA consumption by humans, controversy still exists with respect to the question of whether the...
Psychopharmacology
May 2004
A C Parrott
Not every tablet sold as "ecstasy" contains MDMA (3,4-methylenedioxymethamphetamine). The historical origins and evolution of this mismatch will be reviewed, in order to estimate the proportions of ecstasy tablets containing MDMA at different periods over the past 30 years. Surveys into the pharmacological constituents of ecstasy tablets, dosage levels, and empirical reports of their perceived...
Psychopharmacology
May 2004
K McCardle, S Luebbers, J D Carter et al.
It has been suggested that 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) causes damage to the serotonergic system, and that this damage results in cognitive and mood impairments. To examine the effect of chronic MDMA usage on a wide battery of cognitive tests and psychological abilities and processes. In the present study, the performance of 17 participants with a history of MDMA use was...